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Abstract
Summary Two comorbidity indices were adapted for use in
the FREEDOM trial and significantly correlated with the
number of medications and impaired health status at baseline.
The indices have applications for the analysis of clinical trial
data and would allow for the appropriate adjustment of co-
morbidities when evaluating clinical trial outcomes.
Introduction The purpose of this study is to adapt two pub-
lished comorbidity indices for use with the FREEDOM clinical
trial evaluating postmenopausal women with osteoporosis.
Methods FREEDOMenrolled women aged 60–90 years with a
bone mineral density T-score <−2.5 at the lumbar spine or total
hip and ≥−4.0 at both sites. Comorbidity indices were calculated
using methods described by Sangha (Arthritis Rheum 49:156–
163, 2003) andWolfe (J Rheumatol 37:305–315, 2010) follow-
ing modification. The adapted Sangha index included 12 con-
ditions with a summary score of 0–12; the adapted Wolfe index
included 7 conditions with a weighted summary score of 0–8.
Higher scores indicated greater comorbidity. A panel of clini-
cians independently reviewed subjects’ medical histories using
a systematic process based on Medical Dictionary for
Regulatory Activities (MedDRA) preferred terms to map spec-
ified comorbid conditions. Spearman correlations between the
adapted indices and baseline subject characteristics expected to
be associated with comorbidities were examined.
Results Of the 7808 subjects in this study, 74 % had ≥1 co-
morbidities based on the adapted Sangha or Wolfe comorbid-
ity indices. The mean (SD) adapted Sangha andWolfe comor-
bidity indices were 1.4 (1.2) and 1.4 (1.3), respectively. Both
indices correlated positively with age, body mass index, and
the number of medications (r=0.54 to 0.55) at baseline and
inversely correlated with health-related quality of life (r=
−0.22 to −0.30) (all P<0.0001). Further, when either the
adapted Sangha or Wolfe index was included as a covariate
for assessing mortality over 36 months in the FREEDOM
population, the hazard ratio of the comorbidity index indicated
that the mortality risk increased by 27 or 28 %, respectively,
for each unit increase in the adapted index (both P<0.0001).
Conclusions Our work suggests these comorbidity indices may
be adapted for usewith clinical trial data, thereby allowing for the
appropriate adjustment and reporting of covariates in the evalu-
ation of clinical trial outcomes in an osteoporotic population.
Keywords Comorbidity . Index . Osteoporosis . Sangha
index .Wolfe index
Introduction
The presence or absence of comorbid conditions and the num-
ber of such conditions are important factors in interpreting clin-
ical trial results. In secondary analyses of pooled clinical trial
data designed to answer specific research questions, adjustment
for patients’ comorbidity status can provide critical insights and
may have an impact on the interpretation of the data. Although
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medical history is collected in clinical trials, the information
collected does not lend itself to the calculation of a comorbidity
index. This is in part because, in clinical trials, a patient’s med-
ical history is routinely coded and reported using the Medical
Dictionary for Regulatory Activities (MedDRA) system and is
not available in the form of International Classification of
Diseases, ninth revision (ICD-9) diagnosis codes which are
used in many existing comorbidity indices to determine a pa-
tient’s comorbidity score. For example, one of the most com-
monly used indices, the Charlson Comorbidity Index [1], was
developed based on hospital records and adapted for use with
ICD-9 diagnosis codes [2]. Published indices that provide in-
formation on comorbidities without the need for ICD-9 diagno-
ses can therefore be useful to derive a comorbidity score for
clinical trial patients. However, currently, a comorbidity index
that can be used with MedDRA terms is not available.
Previously, Sangha et al. developed a novel self-
administered questionnaire to assess comorbid conditions in
a clinical setting where medical records are unavailable [3].
Similarly, Wolfe et al. developed an index to assess comorbid-
ities associated with health-related quality of life in four rheu-
matic diseases using self-report questionnaires [4]. Although
both indices are based in rheumatology, each uses patient sur-
vey data versus chart-based data to determine comorbidity
burden. Considering the methodologies used for these indices,
we adapted the Sangha comorbidity index and Wolfe comor-
bidity index for application to clinical trial data.
The FREEDOM clinical trial was a large phase 3, placebo-
controlled study in postmenopausal women with osteoporosis
[5]. As patients’medical histories were coded using MedDRA,
this trial provided an opportunity to apply the Sangha and
Wolfe indices for the purpose of identifying each subjects’ co-
morbidities in the absence of ICD-9 diagnosis codes, and to
report on the comorbidity burden of the population studied.
Here, we present the results from the adapted Sangha and
Wolfe comorbidity indices that were applied to the FREEDOM
clinical trial evaluating postmenopausal womenwith osteoporosis.
Materials and methods
Study design
This was a retrospective analysis of data from the FREEDOM
trial. A systematic approach for incorporating input from a
panel of clinicians was used to map medical history data in
the trial to published indices in order to calculate the comor-
bidity score for each subject in the trial.
Data source
The FREEDOM trial design (ClinicalTrials .gov:
NCT00089791) has been described previously [5]. FREE
DOM was a 3-year, phase 3, international, randomized, dou-
ble-blind, placebo-controlled study. Postmenopausal women
who enrolled were 60 to 90 years old and had a bone mineral
density (BMD) T-score of <−2.5 at the lumbar spine or total
hip, and ≥−4.0 at both sites. Participants received placebo or
60 mg denosumab (Prolia®; Amgen Inc., Thousand Oaks,
CA, USA) subcutaneously every 6 months for 3 years and
were instructed to take calcium (≥1 g) and vitamin D
(≥400 IU) daily.
Identifying and mapping comorbid conditions
in the FREEDOM trial
Medical histories of subjects in the FREEDOM trial were
coded using MedDRA (version 11.0) standardized interna-
tional terminology. Briefly, physicians at study sites reported
medical histories that were coded using MedDRA preferred
terms, which are distinct descriptors for individual medical
concepts that are coded from terms that reflect how an obser-
vation may be reported in practice. Related preferred terms are
further grouped according to a pre-specified hierarchy. The
highest level of organization is composed of 26 system organ
classes (e.g., gastrointestinal disorders, infections and infesta-
tions, musculoskeletal and connective disorders).
Using a pre-specified strategy (Supplementary Fig. S1), a
clinician panel of four physicians (three internal and one ex-
ternal to Amgen Inc.) who specialized in cardiology, internal
medicine, and/or rheumatology mapped selected MedDRA
preferred terms to the comorbid conditions included in the
adapted Sangha and Wolfe indices (Table 1). The following
steps were conducted to arrive at the comorbidity score for
each subject: (1) For each specified comorbid condition, the
clinical panelists independently reviewed the MedDRA pre-
ferred terms within the respective system organ class for the
medical history data collected from all FREEDOM partici-
pants; (2) the preferred terms were then classified and used
to define a specified comorbid condition. In this study, a co-
morbid condition was defined as an illness that required med-
ical treatment, health resource utilization, or affected the ad-
ministration of medication; (3) responses from the panel of
clinicians on the classification of preferred terms were consol-
idated and compared; and (4) any preferred term classification
that was not agreed upon by all four physicians was consid-
ered a classification discrepancy and was discussed and re-
solved among panel physicians, and if needed, adjudicated by
a fifth physician (external to Amgen Inc.) who specialized in
internal medicine and geriatric medicine.
Adaptation of the Sangha and Wolfe indices
Sangha et al. developed a self-administered comorbidity ques-
tionnaire to assess comorbid conditions in clinical and health
services research where medical records are unavailable [3].
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The 13 comorbidities assessed included anemia or other blood
diseases, back pain, cancer, depression, diabetes, heart dis-
ease, high blood pressure, kidney disease, liver disease, lung
disease, arthritis, rheumatoid arthritis, and ulcer or stomach
disease. In the adapted Sangha comorbidity index (range 0–
12), 12 of the 13 original comorbidities were evaluated; back
pain was not included as a comorbid condition of interest
because it was related to the primary outcome of fracture in
the FREEDOM trial. As the original Sangha index was not
weighted, 1 point was assigned for each condition in the
adapted index (Table 1).
Wolfe et al. developed an index to describe comorbidities
with four rheumatic diseases through self-reported question-
naires [4]. The original Wolfe index (range 0–9) was composed
of 11 present or past comorbid conditions including pulmonary
disorders; myocardial infarction (MI); stroke; other cardiovas-
cular (CV) disorders; hypertension; diabetes; spine, hip, and leg
fractures; depression; gastrointestinal disorders; gastrointestinal
ulcer; and cancer. These 11 conditions were then grouped to-
gether and differentially weighted, such that a total of 8 condi-
tions were evaluated as follows: 2 points were assigned to pul-
monary disorders; 2 points were assigned to CV conditions
(including MI, stroke, and other CV disorders); and 1 point
was assigned to all other conditions (diabetes; spine, hip, and
leg fractures; depression; gastrointestinal disorders/
gastrointestinal ulcer; and cancer). In addition, hypertension
was assigned a score of 1 point but only in the absence of any
CV conditions. The adapted Wolfe comorbidity index was
composed of the same, similarly grouped and weighted comor-
bid conditions; however, spine, hip, or leg fractures were not
included as comorbid conditions of interest because they were
related to the primary outcome of fracture in the FREEDOM
trial (Table 1). Therefore, a total of 7 conditions were evaluated
in the adapted Wolfe index with a range of 0–8.
Associations between the comorbidity index and subject
characteristics and mortality
Spearman correlations were used to examine associations be-
tween the derived comorbidity indices and baseline subject
characteristics, including subjects’ health-related quality of
life status which was assessed using the Osteoporosis
Assessment Questionnaire short version (OPAQ-SV) [6]
physical function, emotional status, and back pain dimen-
sions, and the EuroQol-5 Dimensions (EQ-5D) [7] utility in-
dex with items measuring pain, mobility, usual activities, self-
care, and anxiety/depression. The EQ-5D also includes a vi-
sual analog scale (VAS) score for rating overall health status.
The association between the comorbidity index and mortality
was assessed based on the hazard ratio of comorbidity index
as a covariate in a Cox proportional hazard model evaluating
mortality. A P value <0.05 was considered statistically
significant.
Results
The baseline characteristics of the 7808 women enrolled in the
FREEDOM pivotal trial are shown in Table 2. The mean age
of the participants was 72.3 years, and 45 % had a fragility
fracture at baseline (30 % nonvertebral; 24 % vertebral). Of
these subjects, 73.8 % had ≥1 comorbidities based on the
adapted Sangha comorbidity index and 70.8 % had ≥1 comor-
bidities based on the adapted Wolfe comorbidity index. The
mean (standard deviation) adapted Sangha comorbidity index
was 1.4 (1.2) and the mean (standard deviation) adaptedWolfe
comorbidity index was 1.4 (1.3), for all subjects (Table 3).
Based on the adapted Sangha comorbidity index, 26.2% of
the FREEDOM population had a score of 0; 33.7 % had a
score of 1; 23.5 % had a score of 2; 11.5 % had a score of 3;
3.8 % had a score of 4; 1.0 % had a score of 5; and 0.3 % had a
Table 1 Comorbid conditions in Sangha et al. and Wolfe et al., and
weight assignment for consideration in the FREEDOM trial
Weight assignment
Sangha et al.










Osteoarthritis, degenerative arthritis 1
Rheumatoid arthritis 1
Ulcer or stomach disease 1
Wolfe et al.
Pulmonary disorders 2
CV conditions (including MI, stroke,







Gastrointestinal disorders (including ulcer) 1
Cancer 1
CV cardiovascular, MI myocardial infarction
a Diseases not included in the index as they were related to the primary
FREEDOM trial outcome of fracture
b Only included in the index when no other CV conditions were included
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score of 6 (Fig. 1). Based on the adapted Wolfe comorbidity
index, 29.2 % had a score of 0; 29.9 % had a score of 1;
23.5 % had a score of 2; 10.8 % had a score of 3; 4.5 % had
a score of 4; 1.7% had a score of 5; 0.3 % had a score of 6; and
<0.1 % had a score of 7 (Fig. 2).
For subjects in the FREEDOM trial, Spearman correlation
showed significant, but modest, correlations between the
adapted indices with age, body mass index, and the number
of medications at baseline (Table 4). An inverse correlation of
health-related quality of life measures (OPAQ, EQ-5D, and
EQ-5D VAS) with the adapted comorbidity indices was ob-
served, which reached statistical significance. The Spearman
correlation between the two indices was 0.9130 (P<0.0001).
No statistically significant correlations were found between
the indices and the FRAX-calculated 10-year major osteopo-
rotic fracture risk with BMD, nor with the 10-year hip fracture
risk without BMD in the calculation. A significant but modest
correlation was observed with the 10-year major osteoporotic
fracture risk without BMD and the adapted Sangha comorbid-
ity index, but not the adapted Wolfe comorbidity index. A
significant but modest correlation was observed with the 10-
year hip fracture risk with BMD and the adapted Wolfe co-
morbidity index, but not the adapted Sangha comorbidity in-
dex (Table 4). In addition, no statistically significant correla-
tions were found between the indices and the number of prev-
alent vertebral fractures; although, a significant but modest
correlation was observed with the number of prior fragility
fractures at baseline.
When either adapted comorbidity index was included in
the model as a covariate for assessing mortality in the FREE
DOM population at 36 months, the hazard ratio of the comor-
bidity index indicated that the mortality risk in the FREE
DOM population increased by 27 or 28 % for each unit in-
crease in the adapted Sangha or Wolfe comorbidity index,
respectively (both P<0.0001).
Discussion
Comorbidities are important considerations in adjusting for
risk of outcomes in clinical trials and are relevant to the inter-
pretation of clinical trial results. However, most comorbidity
indices currently available are not designed for use with clin-
ical trial data because they are designed to be applied to sec-
ondary databases and rely on ICD-9 codes. Notably, neither
the Sangha nor Wolfe comorbidity indices rely on ICD-9
Table 2 FREEDOM trial subject baseline characteristics




White or Caucasian 7238 (92.7)
Age, years
Mean (SD) 72.3 (5.2)
Age group, n (%)
60 to 64 years 414 (5.3)
65 to 69 years 1644 (21.1)
70 to 74 years 3279 (42.0)
≥75 years 2471 (31.6)
Years since menopause, mean (SD) 24.2 (7.5)
Prior fragility fracture, n (%) 3484 (44.6)
Percentages are based on the number of subjects randomized
N number of subjects randomized, SD standard deviation
Table 3 Distribution of comorbidity indices in the FREEDOM trial
All subjects (N=7808)
Adapted Sangha comorbidity index
Mean (SD) 1.4 (1.2)
Median (min, max) 1 (0, 6)
Adapted Wolfe comorbidity index
Mean (SD) 1.4 (1.3)
Median (min, max) 1 (0, 7)
N number of subjects randomized, SD standard deviation



































Fig. 1 Distribution of adapted Sangha comorbidity index in the FREE
DOM trial. N=7808 aMaximum observed value was 6
 
Adapted Wolfe Comorbidity Index
a


































Fig. 2 Distribution of adapted Wolfe comorbidity index in the FREE
DOM trial. N=7808 aMaximum observed value was 7
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codes and therefore may not be directly applied for use with
clinical trial data.
In this report, the Sangha and Wolfe comorbidity indices
were adapted and applied to FREEDOM clinical trial data to
assess the comorbidity burden in this subject population of
postmenopausal women with osteoporosis. In doing so, we
found a robust correspondence between the two indices. The
comorbidity index for the FREEDOM trial, as assessed by the
adapted indices, ranged between 0 and 7; however, the major-
ity of subjects (60 %) had fewer than two comorbid conditions
given the trial eligibility criteria.
Based on the methodology used here, these adapted indices
could be used to evaluate other disease states as well.
Depending on the trial population of interest, the Wolfe index
offers some potential advantages over the Sangha index. The
Wolfe index allows for the weighting of disorders and more
serious conditions, such as pulmonary and CV disorders, are
assigned higher weights. Further, the Wolfe index can poten-
tially include fracture as another comorbid condition.
However, as the Wolfe index was originally developed in
patients with fibromyalgia, noninflammatory rheumatoid dis-
orders, rheumatoid arthritis, and systemic lupus erythemato-
sus, these conditions were not considered comorbidities and
were thus excluded from the index. Subjects with comorbid
rheumatoid conditions can therefore only be identified using
the Sangha index. Nevertheless, the correlations of the two
indices with baseline characteristics were consistent, suggest-
ing that when applied to osteoporosis trial populations, their
performance is equivalent (or similar).
Limitations of this study include the use of MedDRA to
classify medical diagnoses for the identification of comorbid
conditions. Although MedDRA terms are standardized to en-
sure consistency in use, MedDRA is updated twice annually,
which could prove challenging when attempting to compare
across clinical trials that have used different versions. In addi-
tion, the medical condition review process was dependent on
the reviewer’s opinion and subject to interpretation of the data.
Although consensus agreement had to be reached by the panel
members, a different panel of physicians may make a different
comorbid condition determination.
The approach proposed in this study was also limited by
the medical history information collected or reported in the
case report form (CRF). Pre-existing medical conditions
may or may not be captured on the CRFs in clinical trials.
Unlike claims-based analyses, a subject’s history cannot be
searched for a number of prior years, which may impact the
outcome of interest. In addition, while statistically significant,
some of the observed correlations between the indices and
baseline characteristics were modest (e.g., OPAQ, EQ-5D),
suggesting that the indices may not fully account for the var-
iation in baseline health status. Finally, inclusion and exclu-
sion criteria in a clinical trial usually result in the enrollment of
Table 4 Spearman correlation of subject baseline characteristics with adapted Sangha and Wolfe comorbidity indices in the FREEDOM trial
Adapted Sangha comorbidity indexa Adapted Wolfe comorbidity indexb
Spearman correlation (N=7808) P value Spearman correlation (N=7808) P value
Number of medications taken at baseline 0.552 <0.0001 0.541 <0.0001
OPAQ dimension
Physical function (0 to 100)c −0.296 <0.0001 −0.277 <0.0001
Emotional status (0 to 100)c −0.302 <0.0001 −0.282 <0.0001
Back pain (0 to 100)c −0.243 <0.0001 −0.222 <0.0001
EQ-5D health state index score (−0.594 to 1)c −0.301 <0.0001 −0.278 <0.0001
EQ-5D visual analog scale (0 to 100)c −0.292 <0.0001 −0.263 <0.0001
Body mass index (kg/m2) 0.178 <0.0001 0.165 <0.0001
Age (years) 0.165 <0.0001 0.162 <0.0001
10-year major osteoporotic fracture risk with BMDd −0.012 0.2999 0.017 0.1353
10-year major osteoporotic fracture risk without BMDd −0.025 0.0254 0.005 0.6463
10-year hip fracture risk with BMDd −0.001 0.9364 0.023 0.0395
10-year hip fracture risk without BMDd −0.022 0.0537 0.005 0.6524
Number of prevalent vertebral fractures −0.0003 0.9774 0.003 0.7975
Number of prior fragility fractures 0.039 0.0006 0.046 <0.0001
N number of subjects randomized, BMD bone mineral density, EQ-5D EuroQol-5 Dimensions, OPAQ osteoporosis assessment questionnaire
a Back pain was excluded from the calculation because it was related to the primary outcome of fracture in the FREEDOM trial
b Fracture history was excluded from the calculation because FREEDOM was a fracture study
cA higher score indicates a more preferred health status
d Based on FRAX version 3.1
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patients with fewer comorbidities and, consequently, may rep-
resent a relatively healthier patient populationwhichmay limit
the generalizability of study findings to populations with
greater baseline morbidity.
Despite these limitations, the application of comorbidity
indices to both clinical trials and observational studies could
assist in data interpretation and future research questions, such
as differences in the frequency and type of comorbidities, as
well as comorbidity burden, in patients in populations of in-
terest (e.g., gender, age, geography), both within the trial and
across trials. Recent research has shown that there are marked
geographic differences in the prevalence of comorbidities [8]
and that comorbidity burden may also be associated with or
influence clinical outcomes [9]. For secondary analyses of
trial data that are aimed at answering research questions that
require adjustment of subjects’ comorbidity status, the adap-
tation of the Wolfe and Sangha indices offers an approach to
determine the comorbidity index of a subject in the absence of
ICD-9 diagnosis codes. Additional studies are needed to de-
termine if these methodologies, when applied to claims data,
result in comparable identification of patients’ comorbidity
status and may serve as a potential validation of the adapted
indices. However, of note, our evaluation of mortality during
the FREEDOM trial using the adapted Wolfe and Sangha
indices to adjust for comorbidity showed that there was a
significant positive correlation between comorbidity and mor-
tality. These data demonstrate that these adapted indices work
well as predictors of mortality.
In conclusion, we adapted two existing comorbidity indices
to evaluate and characterize an osteoporosis trial population,
applied them to the FREEDOM phase 3 clinical trial, and
found a high correlation between the two adapted indices.
These data suggest that it is possible to adapt existing comor-
bidity indices to assess comorbidity burden in other disease
states and randomized clinical trials. Application of these in-
dices to clinical trials would allow for a more comprehensive
description of the trial population and provide a means for
more complete interpretation of clinical trial results and sup-
plemental secondary analyses of clinical trial data that require
adjustment for comorbidities.
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